
Validea's guru fundamental report indicates that Gilead Sciences (GILD) receives a 100% rating based on their Twin Momentum Investor model, which is based on the strategy of Dashan Huang and combines fundamental and price momentum. The model identifies strong fundamental momentum and positive twelve-minus-one momentum for GILD, suggesting the stock meets the criteria for potential market outperformance based on Huang's research. Huang's research showed that stocks exhibiting both price and fundamental momentum outperform the market.
Gilead Sciences Inc. (GILD) has received a perfect 100% rating from Validea's Twin Momentum Investor model, a quantitative strategy developed by Dashan Huang that screens for stocks exhibiting both strong fundamental momentum and positive price momentum. This top rating signifies strong interest from the model, as scores above 90% are considered indicative of such. GILD, a large-cap growth stock in the Biotechnology & Drugs industry, successfully passed the model's specific criteria for 'Fundamental Momentum' and 'Twelve Minus One Momentum.' Huang's research, which underpins this model, identified seven fundamental variables (earnings, return on equity, return on assets, accrual operating profitability to equity, cash operating profitability to assets, gross profit to assets, and net payout ratio) that, when combined into a single fundamental momentum measure and paired with price momentum, historically demonstrated an ability to double market outperformance. The strongly positive sentiment score of 0.85 for GILD aligns with this quantitative assessment, further underscoring the positive signals generated by this specific analytical framework.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment